Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 5/20 | 0.67 |
| ▸ | KDM1A | O60341 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.54 |
| ▸ | MEN1 | O00255 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | HTT | P42858 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | RRM1 | P23921 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL684758 | 0.88 | PIK3CG (0.67) | PIK3CGKDM1AKMT2AMEN1MAPT | |
| SCHEMBL684653 | 0.85 | KMT2A (0.67) | KDM1AKMT2AMEN1MAPTHTT | |
| SCHEMBL684238 | 0.85 | PIK3CG (0.75) | PIK3CGKMT2AMEN1MAPTHTT | |
| SCHEMBL684969 | 0.85 | KDM1A (0.61) | KDM1AKMT2AMEN1MAPTHTT | |
| SCHEMBL683982 | 0.84 | CYP1A2 (0.63) | KDM1AKMT2AMEN1MAPTHTT | |
| SCHEMBL684718 | 0.79 | PIK3CG (0.84) | PIK3CGKDM1AKMT2AMEN1MAPT | |
| SCHEMBL685304 | 0.78 | PIK3CG (0.59) | PIK3CGKMT2AMEN1MAPTHTT | |
| SCHEMBL683923 | 0.78 | PIK3CG (1.00) | PIK3CGKDM1AKMT2AMEN1MAPT | |
| SCHEMBL684751 | 0.78 | PIK3CG (0.71) | PIK3CGKMT2AMEN1MAPTHTT | |
| SCHEMBL684571 | 0.78 | CYP1A2 (0.61) | KDM1AKMT2AMEN1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8715745-B2 | Fungicidal compositions including hydrazone derivatives and copper | DOW AGROSCIENCES, LLC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8715745-B2 | Fungicidal compositions including hydrazone derivatives and copper | DOW AGROSCIENCES, LLC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20120010075-A1 | SYNERGISTIC FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER | DOW AGROSCIENCES LLC (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120009274-A1 | FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER | DOW AGROSCIENCES LLC (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120009274-A1 | FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER | DOW AGROSCIENCES LLC (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010075-A1 | SYNERGISTIC FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER | SOD1, CYP51A1, SOD3 | PIK3CG 2876/4885KDM1A 484/4885KMT2A 1362/4885 |
| US-20120009274-A1 | FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER | SOD1, CYP51A1, CYP4Z1 | PIK3CG 2911/4885KDM1A 291/4885KMT2A 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.